Sagimet Biosciences Inc. Operating Cash Flow
Sagimet Biosciences Inc. (SGMT) reported Operating Cash Flow of -$19.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Sagimet Biosciences Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$11.10M.
- Sagimet Biosciences Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$8.61M.
- Sagimet Biosciences Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$11.83M.
- Sagimet Biosciences Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$10.18M.
- Sagimet Biosciences Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$45.65M.
- Sagimet Biosciences Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$42.44M.
- Sagimet Biosciences Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$23.77M.
- Sagimet Biosciences Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$24.49M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$11.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$19.71M 10-Q · filed 2026-08-11 | -$31.54M derived: sum of 3 quarters · filed 2026-08-11 | -$41.72M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$8.61M 10-Q · filed 2026-05-12 | -$20.44M derived: sum of 2 quarters · filed 2026-05-12 | -$30.62M derived: sum of 3 quarters · filed 2026-05-12 | -$39.73M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$11.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$22.01M derived: sum of 2 quarters · filed 2026-03-11 | -$31.11M derived: sum of 3 quarters · filed 2026-08-11 | -$45.65M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$10.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$19.28M derived: sum of 2 quarters · filed 2026-08-11 | -$33.82M 10-Q · filed 2025-11-13 | -$44.84M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$9.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$23.64M 10-Q · filed 2026-08-11 | -$34.66M derived: sum of 3 quarters · filed 2026-08-11 | -$54.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$14.54M 10-Q · filed 2026-05-12 | -$25.56M derived: sum of 2 quarters · filed 2026-05-12 | -$45.13M derived: sum of 3 quarters · filed 2026-05-12 | -$50.76M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$11.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$30.59M derived: sum of 2 quarters · filed 2026-03-11 | -$36.23M derived: sum of 3 quarters · filed 2026-03-11 | -$42.44M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$19.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$25.20M derived: sum of 2 quarters · filed 2025-11-13 | -$31.41M 10-Q · filed 2025-11-13 | -$38.49M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$5.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$11.84M 10-Q · filed 2025-08-13 | -$18.93M derived: sum of 3 quarters · filed 2025-08-13 | -$22.80M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$6.21M 10-Q · filed 2025-05-08 | -$13.29M derived: sum of 2 quarters · filed 2025-05-08 | -$17.17M derived: sum of 3 quarters · filed 2025-05-08 | -$22.89M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$7.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$10.96M derived: sum of 2 quarters · filed 2025-03-12 | -$16.68M derived: sum of 3 quarters · filed 2025-03-12 | -$23.77M 10-K · filed 2025-03-12 |
| 2023-09-30 | -$3.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$9.60M derived: sum of 2 quarters · filed 2024-11-14 | -$16.68M 10-Q · filed 2024-11-14 | -$24.14M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$5.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$12.80M 10-Q · filed 2024-08-14 | -$20.26M derived: sum of 3 quarters · filed 2024-08-14 | -$26.49M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$7.08M 10-Q · filed 2024-05-15 | -$14.54M derived: sum of 2 quarters · filed 2024-05-15 | -$20.77M derived: sum of 3 quarters · filed 2024-05-15 | -$20.77M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$7.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$13.69M derived: sum of 2 quarters · filed 2024-03-25 | -$13.69M derived: sum of 3 quarters · filed 2024-03-25 | -$24.49M 10-K · filed 2024-03-25 |
| 2022-09-30 | -$6.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$6.24M derived: sum of 2 quarters · filed 2023-11-13 | -$17.04M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$10.80M 10-Q · filed 2023-08-21 | ||
| 2022-03-31 | -$10.80M 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |